Yonsei Med J.  2011 May;52(3):482-487. 10.3349/ymj.2011.52.3.482.

Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus: Experience in a Tertiary Hospital

• Lee SJ
• Choi HK
• Son J
• Kim KH
• Lee SH

• KMID: 1777021
• DOI: http://doi.org/10.3349/ymj.2011.52.3.482

Abstract

PURPOSE
Cryptococcal meningitis is a relatively common opportunistic infection in human immunodeficiency virus (HIV) patients and it can frequently occur in immunocompetent hosts without any apparent underlying disease. Nevertheless, little is known about cyptococcal meningitis in the Korean population. The purpose of this study was to evaluate the clinical features and initial laboratory findings of cryptococcal meningitis in patients with and without HIV at a tertiary care teaching hospital.
MATERIALS AND METHODS
We performed a retrospective study at a tertiary care teaching hospital from January 2001 to December 2009. Eleven HIV positive patients and nine HIV negative patients were included.
RESULTS
The most common symptoms were headache and fever in cryptococcal meningitis, and diabetic mellitus, end stage renal disease and liver cirrhosis were the main associated conditions in patients without HIV. Patients with HIV showed lower peripheral CD4+ cell counts (median: 9, range: 1-107) and a higher burden of cryptococcus than patients without HIV. There were no statistically significant differences in serum CRP level and other cerebrospinal fluid parameters between patients with HIV and without HIV. The in-hospital mortality was 10%, and recurrence of cyptococcal meningitis was observed in 3 patients with HIV and this occurred within 5 months of the first episode.
CONCLUSION
Cryptococcal meningitis is fatal without treatment, therefore, rapid recognition of symptoms such as fever and headache and diagnosis is required to decrease the mortality. Recurrence of meningitis after treatment should carefully be followed up, especially in advanced HIV patients.

Keyword

Cryptococcal meningitis; HIV; neurologic symptom

MeSH Terms

Adult
Aged
Comorbidity
Female
HIV Infections/*complications
Hospitals
Humans
Male
Meningitis, Cryptococcal/diagnosis/*epidemiology
Middle Aged
Republic of Korea/epidemiology
Retrospective Studies

Reference

1. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991. 13:1163–1169.

2. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am. 2002. 16:837–874.

3. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001. 33:690–699.

4. Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Infect Dis. 1966. 116:75–83.

5. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974. 112:2260–2270.

6. Jarvis JN, Harrison TS. HIV associated cryptococcal meningitis. AIDS. 2007. 21:2119–2129.

7. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000. 30:47–54.

8. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. The NIAID Mycoses Study Group. the AIDS Clinical Trials Group. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992. 326:83–89.

9. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000. 30:710–718.

10. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2005. 72:99–118.

11. Cox GM, Perfect JR. Edward LA, editor. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. Topley and Wilson's Microbiology and Microbial Infections. 1997. 9th ed. London: Arnold Press.

12. Kisenge PR, Hawkins AT, Maro VP, MeHele JP, Swai NS, Mueller A, et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007. 7:39.

13. Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994. 32:1680–1684.

14. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV infected persons. J Acquir Immune Defic Syndr. 1991. 4:770–776.

15. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. National Institute of Allergy and Infectious Disease Mycoses Study Group. AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997. 337:15–21.

16. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006. 20:2183–2191.

17. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet. 2004. 363:1764–1767.

18. Robinson PA, Bauer M, Leal MA, Evans SG, Holtom PD, Diamond DA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999. 28:82–92.

19. Choi KG, Choi IS, Kim KH. A clinical study of cryptococcal infection. J Korean Neurol Assoc. 1984. 2:14–20.